{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:37:21Z","timestamp":1778661441752,"version":"3.51.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,10,12]],"date-time":"2010-10-12T00:00:00Z","timestamp":1286841600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Immunol"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1186\/1471-2172-11-49","type":"journal-article","created":{"date-parts":[[2010,10,28]],"date-time":"2010-10-28T06:14:32Z","timestamp":1288246472000},"source":"Crossref","is-referenced-by-count":24,"title":["Natural killer cells are crucial for the efficacy of Icon (factor VII\/human IgG1 Fc) immunotherapy in human tongue cancer"],"prefix":"10.1186","volume":"11","author":[{"given":"Zhiwei","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,10,12]]},"reference":[{"key":"333_CR1","first-page":"39","volume":"1654","author":"P Alessi","year":"2004","unstructured":"Alessi P, Ebbinghaus C, Neri D: Molecular targeting of angiogenesis. Biochim Biophys Acta. 2004, 1654: 39-49.","journal-title":"Biochim Biophys Acta"},{"key":"333_CR2","first-page":"S127","volume":"2","author":"J Folkman","year":"2003","unstructured":"Folkman J: Angiogenesis inhibitors: a new class of drugs. Cancer Biol Ther. 2003, 2: S127-33.","journal-title":"Cancer Biol Ther"},{"key":"333_CR3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.clon.2007.03.014","volume":"19","author":"DM Patterson","year":"2007","unstructured":"Patterson DM, Rustin GJ: Vascular damaging agents. Clin Oncol (R Coll Radiol). 2007, 19: 443-56.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"333_CR4","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/jcb.20783","volume":"99","author":"MJ Pilat","year":"2006","unstructured":"Pilat MJ, Lorusso PM: Vascular disrupting agents. J Cell Biochem. 2006, 99: 1021-39. 10.1002\/jcb.20783.","journal-title":"J Cell Biochem"},{"key":"333_CR5","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1158\/1078-0432.416.11.2","volume":"11","author":"DW Siemann","year":"2005","unstructured":"Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FA, Horsman MR, Marme D, Lorusso PM: Differentiation and definition of vascular-targeted therapies. Clin Cancer Res. 2005, 11: 416-20.","journal-title":"Clin Cancer Res"},{"key":"333_CR6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1158\/1078-0432.CCR-0642-03","volume":"10","author":"PE Thorpe","year":"2004","unstructured":"Thorpe PE: Vascular targeting agents as cancer therapeutics. Clin Cancer Res. 2004, 10: 415-27. 10.1158\/1078-0432.CCR-0642-03.","journal-title":"Clin Cancer Res"},{"key":"333_CR7","doi-asserted-by":"publisher","first-page":"11520","DOI":"10.1158\/0008-5472.CAN-06-2848","volume":"66","author":"MR Horsman","year":"2006","unstructured":"Horsman MR, Siemann DW: Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res. 2006, 66: 11520-39. 10.1158\/0008-5472.CAN-06-2848.","journal-title":"Cancer Res"},{"key":"333_CR8","doi-asserted-by":"publisher","first-page":"8161","DOI":"10.1073\/pnas.96.14.8161","volume":"96","author":"Z Hu","year":"1999","unstructured":"Hu Z, Sun Y, Garen A: Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model. Proc Natl Acad Sci USA. 1999, 96: 8161-6. 10.1073\/pnas.96.14.8161.","journal-title":"Proc Natl Acad Sci USA"},{"key":"333_CR9","doi-asserted-by":"publisher","first-page":"9221","DOI":"10.1073\/pnas.97.16.9221","volume":"97","author":"Z Hu","year":"2000","unstructured":"Hu Z, Garen A: Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugates for cancer immunotherapy. Proc Natl Acad Sci USA. 2000, 97: 9221-5. 10.1073\/pnas.97.16.9221.","journal-title":"Proc Natl Acad Sci USA"},{"key":"333_CR10","doi-asserted-by":"publisher","first-page":"12180","DOI":"10.1073\/pnas.201420298","volume":"98","author":"Z Hu","year":"2001","unstructured":"Hu Z, Garen A: Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer. Proc Natl Acad Sci USA. 2001, 98: 12180-5. 10.1073\/pnas.201420298.","journal-title":"Proc Natl Acad Sci USA"},{"key":"333_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0092-8674(87)90669-6","volume":"50","author":"JH Morrissey","year":"1987","unstructured":"Morrissey JH, Fakhrai H, Edgington TS: Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade. Cell. 1987, 50: 129-35. 10.1016\/0092-8674(87)90669-6.","journal-title":"Cell"},{"key":"333_CR12","doi-asserted-by":"publisher","first-page":"5148","DOI":"10.1073\/pnas.84.15.5148","volume":"84","author":"EK Spicer","year":"1987","unstructured":"Spicer EK, Horton R, Bloem L, Bach R, Williams KR, Guha A, Kraus J, Lin TC, Nemerson Y, Konigsberg WH: Isolation of cDNA clones coding for human tissue factor: primary structure of the protein and cDNA. Proc Natl Acad Sci USA. 1987, 84: 5148-52. 10.1073\/pnas.84.15.5148.","journal-title":"Proc Natl Acad Sci USA"},{"key":"333_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nm0296-209","volume":"2","author":"J Contrino","year":"1996","unstructured":"Contrino J, Hair G, Kreutzer DL, Rickles FR: In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med. 1996, 2: 209-15. 10.1038\/nm0296-209.","journal-title":"Nat Med"},{"key":"333_CR14","first-page":"399","volume":"152","author":"M Shoji","year":"1998","unstructured":"Shoji M, Hancock WW, Abe K, Micko C, Casper KA, Baine RM, Wilcox JN, Danave I, Dillehay DL, Matthews E, et al.,: Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol. 1998, 152: 399-411.","journal-title":"Am J Pathol"},{"key":"333_CR15","first-page":"1029","volume":"146","author":"HF Dvorak","year":"1995","unstructured":"Dvorak HF, Brown LF, Detmar M, Dvorak AM: Vascular permeability factor\/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995, 146: 1029-39.","journal-title":"Am J Pathol"},{"key":"333_CR16","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/(SICI)1097-0215(19980302)75:5<780::AID-IJC19>3.0.CO;2-A","volume":"75","author":"S Zucker","year":"1998","unstructured":"Zucker S, Mirza H, Conner CE, Lorenz AF, Drews MH, Bahou WF, Jesty J: Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Int J Cancer. 1998, 75: 780-6. 10.1002\/(SICI)1097-0215(19980302)75:5<780::AID-IJC19>3.0.CO;2-A.","journal-title":"Int J Cancer"},{"key":"333_CR17","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1055\/s-0038-1657624","volume":"78","author":"B Osterud","year":"1997","unstructured":"Osterud B: Tissue factor: a complex biological role. Thromb Haemost. 1997, 78: 755-8.","journal-title":"Thromb Haemost"},{"key":"333_CR18","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1055\/s-0038-1657625","volume":"78","author":"N Semeraro","year":"1997","unstructured":"Semeraro N, Colucci M: Tissue factor in health and disease. Thromb Haemost. 1997, 78: 759-64.","journal-title":"Thromb Haemost"},{"issue":"1","key":"333_CR19","first-page":"S27","volume":"9","author":"LV Rao","year":"1998","unstructured":"Rao LV, Pendurthi UR: Tissue factor on cells. Blood Coagul Fibrinolysis. 1998, 9 (1): S27-35.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"333_CR20","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/0049-3848(95)00192-T","volume":"80","author":"AB Mulder","year":"1995","unstructured":"Mulder AB, Blom NR, Smit JW, Ruiters MH, van der Meer J, Halie MR, Bom VJ: Basal tissue factor expression in endothelial cell cultures is caused by contaminating smooth muscle cells. Reduction by using chymotrypsin instead of collagenase. Thromb Res. 1995, 80: 399-411. 10.1016\/0049-3848(95)00192-T.","journal-title":"Thromb Res"},{"key":"333_CR21","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1021\/bi00131a015","volume":"31","author":"E Waxman","year":"1992","unstructured":"Waxman E, Ross JB, Laue TM, Guha A, Thiruvikraman SV, Lin TC, Konigsberg WH, Nemerson Y: Tissue factor and its extracellular soluble domain: the relationship between intermolecular association with factor VIIa and enzymatic activity of the complex. Biochemistry. 1992, 31: 3998-4003. 10.1021\/bi00131a015.","journal-title":"Biochemistry"},{"key":"333_CR22","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1055\/s-0037-1615593","volume":"85","author":"L Presta","year":"2001","unstructured":"Presta L, Sims P, Meng YG, Moran P, Bullens S, Bunting S, Schoenfeld J, Lowe D, Lai J, Rancatore P, et al.,: Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeutic. Thromb Haemost. 2001, 85: 379-89.","journal-title":"Thromb Haemost"},{"key":"333_CR23","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/sj.cgt.7701030","volume":"14","author":"Y Tang","year":"2007","unstructured":"Tang Y, Borgstrom P, Maynard J, Koziol J, Hu Z, Garen A, Deisseroth A: Mapping of angiogenic markers for targeting of vectors to tumor vascular endothelial cells. Cancer Gene Ther. 2007, 14: 346-53. 10.1038\/sj.cgt.7701030.","journal-title":"Cancer Gene Ther"},{"key":"333_CR24","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1073\/pnas.0438014100","volume":"100","author":"PS Bora","year":"2003","unstructured":"Bora PS, Hu Z, Tezel TH, Sohn JH, Kang SG, Cruz JM, Bora NS, Garen A, Kaplan HJ: Immunotherapy for choroidal neovascularization in a laser-induced mouse model simulating exudative (wet) macular degeneration. Proc Natl Acad Sci USA. 2003, 100: 2679-84. 10.1073\/pnas.0438014100.","journal-title":"Proc Natl Acad Sci USA"},{"key":"333_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/09273940601147760","volume":"15","author":"TH Tezel","year":"2007","unstructured":"Tezel TH, Bodek E, Sonmez K, Kaliappan S, Kaplan HJ, Hu Z, Garen A: Targeting tissue factor for immunotherapy of choroidal neovascularization by intravitreal delivery of factor VII-Fc chimeric antibody. Ocul Immunol Inflamm. 2007, 15: 3-10. 10.1080\/09273940601147760.","journal-title":"Ocul Immunol Inflamm"},{"key":"333_CR26","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.2353\/ajpath.2010.090757","volume":"176","author":"G Krikun","year":"2010","unstructured":"Krikun G, Hu Z, Osteen K, Bruner-Tran KL, Schatz F, Taylor HS, Toti P, Arcuri F, Konigsberg W, Garen A, et al.,: The immunoconjugate \"icon\" targets aberrantly expressed endothelial tissue factor causing regression of endometriosis. Am J Pathol. 2010, 176: 1050-6. 10.2353\/ajpath.2010.090757.","journal-title":"Am J Pathol"},{"key":"333_CR27","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/sj.bjc.6605760","volume":"103","author":"E Cocco","year":"2010","unstructured":"Cocco E, Hu Z, Richter CE, Bellone S, Casagrande F, Bellone M, Todeschini P, Krikun G, Silasi DA, Azodi M, et al.,: hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma. Br J Cancer. 2010, 103: 812-9. 10.1038\/sj.bjc.6605760.","journal-title":"Br J Cancer"},{"key":"333_CR28","first-page":"112","volume":"8","author":"XQ Xu","year":"1986","unstructured":"Xu XQ: [Chromosome study on the Tca8113 cell line derived from squamous cell carcinoma of the human tongue]. Zhonghua Zhong Liu Za Zhi. 1986, 8: 112-4.","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"333_CR29","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/301527a0","volume":"301","author":"GC Bosma","year":"1983","unstructured":"Bosma GC, Custer RP, Bosma MJ: A severe combined immunodeficiency mutation in the mouse. Nature. 1983, 301: 527-30. 10.1038\/301527a0.","journal-title":"Nature"},{"key":"333_CR30","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.4049\/jimmunol.134.6.3798","volume":"134","author":"K Dorshkind","year":"1985","unstructured":"Dorshkind K, Pollack SB, Bosma MJ, Phillips RA: Natural killer (NK) cells are present in mice with severe combined immunodeficiency (scid). J Immunol. 1985, 134: 3798-801.","journal-title":"J Immunol"},{"key":"333_CR31","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/278451a0","volume":"278","author":"J Roder","year":"1979","unstructured":"Roder J, Duwe A: The beige mutation in the mouse selectively impairs natural killer cell function. Nature. 1979, 278: 451-3. 10.1038\/278451a0.","journal-title":"Nature"},{"key":"333_CR32","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/0008-8749(90)90165-N","volume":"130","author":"JR MacDougall","year":"1990","unstructured":"MacDougall JR, Croy BA, Chapeau C, Clark DA: Demonstration of a splenic cytotoxic effector cell in mice of genotype SCID\/SCID.BG\/BG. Cell Immunol. 1990, 130: 106-17. 10.1016\/0008-8749(90)90165-N.","journal-title":"Cell Immunol"},{"key":"333_CR33","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.4049\/jimmunol.167.3.1141","volume":"167","author":"H Arase","year":"2001","unstructured":"Arase H, Saito T, Phillips JH, Lanier LL: Cutting edge: the mouse NK cell-associated antigen recognized by DX5 monoclonal antibody is CD49b (alpha 2 integrin, very late antigen-2). J Immunol. 2001, 167: 1141-4.","journal-title":"J Immunol"},{"key":"333_CR34","doi-asserted-by":"crossref","first-page":"549","DOI":"10.4049\/jimmunol.157.2.549","volume":"157","author":"MB Fischer","year":"1996","unstructured":"Fischer MB, Ma M, Goerg S, Zhou X, Xia J, Finco O, Han S, Kelsoe G, Howard RG, Rothstein TL, et al.,: Regulation of the B cell response to T-dependent antigens by classical pathway complement. J Immunol. 1996, 157: 549-56.","journal-title":"J Immunol"},{"key":"333_CR35","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.1073\/pnas.89.10.4285","volume":"89","author":"P Carter","year":"1992","unstructured":"Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 1992, 89: 4285-9. 10.1073\/pnas.89.10.4285.","journal-title":"Proc Natl Acad Sci USA"},{"key":"333_CR36","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","volume":"83","author":"ME Reff","year":"1994","unstructured":"Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994, 83: 435-45.","journal-title":"Blood"},{"key":"333_CR37","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1158\/1078-0432.CCR-06-1726","volume":"13","author":"J Kurai","year":"2007","unstructured":"Kurai J, Chikumi H, Hashimoto K, Yamaguchi K, Yamasaki A, Sako T, Touge H, Makino H, Takata M, Miyata M, et al.,: Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res. 2007, 13: 1552-61. 10.1158\/1078-0432.CCR-06-1726.","journal-title":"Clin Cancer Res"},{"key":"333_CR38","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1600-065X.1979.tb00267.x","volume":"44","author":"RB Herberman","year":"1979","unstructured":"Herberman RB, Djeu J, Kay HD, Ortaldo JR, Riccardi C, Bonnard GD, Holden HT, Fagnani R, Santoni A, Puccetti P: Natural killer cells: characteristics and regulation of activity. Immunol Rev. 1979, 44: 43-70. 10.1111\/j.1600-065X.1979.tb00267.x.","journal-title":"Immunol Rev"},{"key":"333_CR39","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jss.2006.08.037","volume":"139","author":"KA Varker","year":"2007","unstructured":"Varker KA, Terrell CE, Welt M, Suleiman S, Thornton L, Andersen BL, Carson WE: Impaired natural killer cell lysis in breast cancer patients with high levels of psychological stress is associated with altered expression of killer immunoglobin-like receptors. J Surg Res. 2007, 139: 36-44. 10.1016\/j.jss.2006.08.037.","journal-title":"J Surg Res"},{"key":"333_CR40","first-page":"5813","volume":"62","author":"K Kono","year":"2002","unstructured":"Kono K, Takahashi A, Ichihara F, Sugai H, Fujii H, Matsumoto Y: Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res. 2002, 62: 5813-7.","journal-title":"Cancer Res"},{"key":"333_CR41","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/sj.bjc.6603885","volume":"97","author":"Y Kawaguchi","year":"2007","unstructured":"Kawaguchi Y, Kono K, Mimura K, Mitsui F, Sugai H, Akaike H, Fujii H: Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. Br J Cancer. 2007, 97: 494-501. 10.1038\/sj.bjc.6603885.","journal-title":"Br J Cancer"},{"key":"333_CR42","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/ijc.22370","volume":"120","author":"Y Kawaguchi","year":"2007","unstructured":"Kawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H, Fujii H: Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer. 2007, 120: 781-7. 10.1002\/ijc.22370.","journal-title":"Int J Cancer"},{"key":"333_CR43","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/bjc.1979.118","volume":"39","author":"TL Ratliff","year":"1979","unstructured":"Ratliff TL, McCool RE, Catalona WJ: Antibody-dependent and spontaneous lympholysis in urologic cancer patients. Br J Cancer. 1979, 39: 667-75.","journal-title":"Br J Cancer"},{"key":"333_CR44","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.4049\/jimmunol.125.3.1216","volume":"125","author":"CD Platsoucas","year":"1980","unstructured":"Platsoucas CD, Fernandes G, Gupta SL, Kempin S, Clarkson B, Good RA, Gupta S: Defective spontaneous and antibody-dependent cytotoxicity mediated by E-rosette-positive and E-rosette-negative cells in untreated patients with chronic lymphocytic leukemia: augmentation by in vitro treatment with interferon. J Immunol. 1980, 125: 1216-23.","journal-title":"J Immunol"},{"key":"333_CR45","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/ijc.2910270310","volume":"27","author":"HW Ziegler","year":"1981","unstructured":"Ziegler HW, Kay NE, Zarling JM: Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia. Int J Cancer. 1981, 27: 321-7. 10.1002\/ijc.2910270310.","journal-title":"Int J Cancer"},{"key":"333_CR46","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1182\/blood.V63.2.305.305","volume":"63","author":"NE Kay","year":"1984","unstructured":"Kay NE, Zarling JM: Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells. Blood. 1984, 63: 305-9.","journal-title":"Blood"},{"key":"333_CR47","first-page":"611","volume":"15","author":"H Matsuzaki","year":"1985","unstructured":"Matsuzaki H, Kagimoto T, Oda T, Kawano F, Takatsuki K: Natural killer activity and antibody-dependent cell-mediated cytotoxicity in multiple myeloma. Jpn J Clin Oncol. 1985, 15: 611-7.","journal-title":"Jpn J Clin Oncol"},{"key":"333_CR48","doi-asserted-by":"publisher","first-page":"6371","DOI":"10.1073\/pnas.80.20.6371","volume":"80","author":"JW Albright","year":"1983","unstructured":"Albright JW, Albright JF: Age-associated impairment of murine natural killer activity. Proc Natl Acad Sci USA. 1983, 80: 6371-5. 10.1073\/pnas.80.20.6371.","journal-title":"Proc Natl Acad Sci USA"},{"key":"333_CR49","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/bcr1612","volume":"8","author":"R Nahta","year":"2006","unstructured":"Nahta R, Esteva FJ: HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res. 2006, 8: 215-10.1186\/bcr1612.","journal-title":"Breast Cancer Res"},{"key":"333_CR50","doi-asserted-by":"publisher","first-page":"11991","DOI":"10.1158\/0008-5472.CAN-07-2068","volume":"67","author":"S Varchetta","year":"2007","unstructured":"Varchetta S, Gibelli N, Oliviero B, Nardini E, Gennari R, Gatti G, Silva LS, Villani L, Tagliabue E, Menard S, et al.,: Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res. 2007, 67: 11991-9. 10.1158\/0008-5472.CAN-07-2068.","journal-title":"Cancer Res"},{"key":"333_CR51","first-page":"607","volume":"1","author":"J Lister","year":"1995","unstructured":"Lister J, Rybka WB, Donnenberg AD, deMagalhaes-Silverman M, Pincus SM, Bloom EJ, Elder EM, Ball ED, Whiteside TL: Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period. Clin Cancer Res. 1995, 1: 607-14.","journal-title":"Clin Cancer Res"},{"key":"333_CR52","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/00002371-200001000-00018","volume":"23","author":"M deMagalhaes-Silverman","year":"2000","unstructured":"deMagalhaes-Silverman M, Donnenberg A, Lembersky B, Elder E, Lister J, Rybka W, Whiteside T, Ball E: Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer. J Immunother. 2000, 23: 154-60. 10.1097\/00002371-200001000-00018.","journal-title":"J Immunother"},{"key":"333_CR53","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1007\/s00262-010-0896-z","volume":"59","author":"V Bachanova","year":"2010","unstructured":"Bachanova V, Burns LJ, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lindgren BR, Cooley S, Weisdorf D, Miller JS: Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunother. 2010, 59: 1739-44. 10.1007\/s00262-010-0896-z.","journal-title":"Cancer Immunol Immunother"},{"key":"333_CR54","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1002\/1521-4141(2001010)31:10<3016::AID-IMMU3016>3.0.CO;2-J","volume":"31","author":"WE Carson","year":"2001","unstructured":"Carson WE, Parihar R, Lindemann MJ, Personeni N, Dierksheide J, Meropol NJ, Baselga J, Caligiuri MA: Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2\/neu-positive breast cancer cells. Eur J Immunol. 2001, 31: 3016-25. 10.1002\/1521-4141(2001010)31:10<3016::AID-IMMU3016>3.0.CO;2-J.","journal-title":"Eur J Immunol"},{"key":"333_CR55","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/0076-6879(93)22029-F","volume":"222","author":"KL Berkner","year":"1993","unstructured":"Berkner KL: Expression of recombinant vitamin K-dependent proteins in mammalian cells: factors IX and VII. Methods Enzymol. 1993, 222: 450-77. full_text.","journal-title":"Methods Enzymol"},{"key":"333_CR56","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/11400","volume":"5","author":"C Nyberg-Hoffman","year":"1999","unstructured":"Nyberg-Hoffman C, Aguilar-Cordova E: Instability of adenoviral vectors during transport and its implication for clinical studies. Nat Med. 1999, 5: 955-7. 10.1038\/11400.","journal-title":"Nat Med"},{"key":"333_CR57","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1126\/science.144.3620.868","volume":"144","author":"RL Walford","year":"1964","unstructured":"Walford RL, Gallagher R, Sjaarda JR: Serologic Typing of Human Lymphocytes with Immune Serum Obtained after Homografting. Science. 1964, 144: 868-70. 10.1126\/science.144.3620.868.","journal-title":"Science"}],"container-title":["BMC Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2172-11-49.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2172-11-49\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2172-11-49.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T01:43:31Z","timestamp":1685843011000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcimmunol.biomedcentral.com\/articles\/10.1186\/1471-2172-11-49"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,12]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["333"],"URL":"https:\/\/doi.org\/10.1186\/1471-2172-11-49","relation":{},"ISSN":["1471-2172"],"issn-type":[{"value":"1471-2172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,12]]},"article-number":"49"}}